Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
132.22
-0.43 (-0.32%)
At close: Aug 29, 2025, 4:00 PM
132.22
0.00 (0.00%)
After-hours: Aug 29, 2025, 4:20 PM EDT
Biogen Revenue
Biogen had revenue of $2.65B in the quarter ending June 30, 2025, with 7.33% growth. This brings the company's revenue in the last twelve months to $10.00B, up 3.36% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$10.00B
Revenue Growth
+3.36%
P/S Ratio
1.94
Revenue / Employee
$1,314,530
Employees
7,605
Market Cap
19.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BIIB News
- 1 day ago - FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi - Reuters
- 4 days ago - Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - Business Wire
- 4 days ago - Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - GlobeNewsWire
- 4 days ago - Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab) - GlobeNewsWire
- 18 days ago - Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - GlobeNewsWire
- 18 days ago - Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Business Wire
- 27 days ago - Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio - Seeking Alpha
- 4 weeks ago - Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript - Seeking Alpha